Ophthalmology’s most life-changing procedures revealed

Seventy-five percent of ophthalmic interventions investigated in a major study have shown evidence of improving quality of life for patients with eye disease, with cataract surgery and anti-VEGF therapy singled out as some of the most important procedures. Read more

Roche’s faricimab meets primary endpoint in DME trial

Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more